US EditionPublished • loading... • Updated
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
BioMarin plans to use $850 million in senior notes and $2 billion in term loans to fund its pending acquisition of Amicus Therapeutics, with a special redemption trigger if not completed by Dec. 19.
- On Jan. 29, 2026, BioMarin Pharmaceutical Inc., San Rafael, California, priced a private offering of $850 million of 5.500% senior unsecured notes due 2034, the company said.
- Completed syndication of a new Term Loan B Facility alongside additional loans and a New Revolving Facility may provide up to $150 million for fees supporting Amicus Therapeutics, Inc. acquisition.
- Gross proceeds will be deposited into an escrow account at closing, pending consummation of the Acquisition, and the unregistered offering is limited to qualified institutional buyers and non-U.S. persons.
- Indenture terms and a special redemption trigger mean BioMarin may have to redeem the Notes if the Acquisition misses specified deadlines, and indenture covenants restrict debt while guarantor subsidiaries back New Senior Secured Credit Facilities.
- The offering is expected to close on February 12, 2026, subject to customary conditions, but the press release cautions forward-looking statements involve risks and no assurance of closing.
Insights by Ground AI
11 Articles
11 Articles
Helena Independent Record+9 Reposted by 9 other sources
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the…
·Helena, United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left1Leaning Right1Center5Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
